PMID- 22776213
OWN - NLM
STAT- MEDLINE
DCOM- 20121207
LR  - 20130118
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 30
IP  - 38
DP  - 2012 Aug 17
TI  - Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model 
      of allergen-driven airway inflammation.
PG  - 5666-74
LID - 10.1016/j.vaccine.2012.06.049 [doi]
AB  - AIM: Intravenous immunoglobulin (IVIG) displays anti-inflammatory activities in 
      many diseases. Subcutaneous administration of anti-IgE in humans provides benefit 
      in severe persistent allergic asthma. Given the well established efficacy of 
      sublingual allergen immunotherapy in respiratory type I allergies, we 
      investigated the therapeutic potential of sublingual immunoglobulin (SLIG), most 
      particularly anti-IgE SLIG, in a murine model of allergen-driven airway 
      inflammation. METHODS: BALB/c mice sensitized with ovalbumin (OVA) were treated 
      sublingually with rat monoclonal IgG1 or IgG2a, either directed to mouse IgE or 
      with no reported specificity. Airway hyperresponsiveness (AHR) was assessed by 
      whole body plethysmography, and eosinophil infiltrates were characterized in 
      bronchial alveolar lavages (BAL). OVA-specific antibody and T cell responses were 
      analyzed in sera and saliva or lung and draining lymph nodes, by ELISA or CBA 
      measurement of cytokine production, respectively. RESULTS: AHR and BAL eosinophil 
      infiltrates were substantially decreased in mice treated sublingually with 
      particulate OVA (positive control), as well as in animals receiving various rat 
      IgG1, irrespective of their specificity for murine IgE. In contrast, no 
      improvement was observed in mice treated with PBS (negative control) or various 
      rat IgG2a. SLIG anti-inflammatory activity is not related to a downregulation of 
      Th2, Th17 or an induction of Foxp3(+) CD4(+) regulatory T cell responses. Mass 
      spectrometry analysis of glycan moieties, such as sialic acid, suggests that the 
      differential efficacy of rat IgG1 and IgG2a is not related to their capacity to 
      interact with lectins borne by oral immune cells. CONCLUSIONS: In a murine model 
      of allergen-driven airway inflammation, SLIG exhibits an anti-inflammatory 
      activity irrespective of the immunoglobulin specificity, and in the absence of 
      allergen. As a noninvasive approach, SLIG deserves to be further studied as a 
      treatment for other inflammatory diseases beyond allergic asthma.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Batard, T
AU  - Batard T
AD  - Stallergenes, 6 rue Alexis de Tocqueville, 92160 Antony, France. 
      tbatard@stallergenes.com
FAU - Zimmer, A
AU  - Zimmer A
FAU - Nony, E
AU  - Nony E
FAU - Bouley, J
AU  - Bouley J
FAU - Airouche, S
AU  - Airouche S
FAU - Luce, S
AU  - Luce S
FAU - Turfkruyer, M
AU  - Turfkruyer M
FAU - Tourdot, S
AU  - Tourdot S
FAU - Mascarell, L
AU  - Mascarell L
FAU - Moingeon, P
AU  - Moingeon P
LA  - eng
PT  - Journal Article
DEP - 20120707
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (anti-IgE antibodies)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Administration, Sublingual
MH  - Animals
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Antibodies, Anti-Idiotypic/*administration & dosage
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Eosinophils/immunology
MH  - Female
MH  - Humans
MH  - Hypersensitivity/*therapy
MH  - Immunoglobulin G/*administration & dosage
MH  - Immunotherapy/*methods
MH  - Lung/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Plethysmography, Whole Body
MH  - Respiratory Tract Diseases/*therapy
MH  - Treatment Outcome
EDAT- 2012/07/11 06:00
MHDA- 2012/12/12 06:00
CRDT- 2012/07/11 06:00
PHST- 2012/01/03 00:00 [received]
PHST- 2012/05/31 00:00 [revised]
PHST- 2012/06/16 00:00 [accepted]
PHST- 2012/07/11 06:00 [entrez]
PHST- 2012/07/11 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - S0264-410X(12)00915-2 [pii]
AID - 10.1016/j.vaccine.2012.06.049 [doi]
PST - ppublish
SO  - Vaccine. 2012 Aug 17;30(38):5666-74. doi: 10.1016/j.vaccine.2012.06.049. Epub 
      2012 Jul 7.